Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer at Rocket Pharmaceuticals (NASDAQ: RCKT), acquired 17,650 shares of company stock on May 7, 2026. The transaction totaled approximately $67,740 at an average price of $3.838 per share.
Details of the Insider Purchase
Chaudhuri made the purchase to cover tax obligations from the vesting of restricted stock units (RSUs). Following this transaction, she directly holds 267,510 shares. These holdings include RSUs that convert on a one-for-one basis into common stock upon vesting.
Stock Performance Overview
The shares currently trade at $3.59, reflecting a 49% decline over the past year. Recent analysis suggests the company remains undervalued relative to its fundamentals.
Key Company Milestones
Rocket Pharmaceuticals recently finalized a deal to sell priority review vouchers for rare pediatric diseases for $180 million. This sale followed the U.S. FDA’s accelerated approval of esladi for the treatment of Leukocyte Adhesion Deficiency-I (LAD-1). The approval extends revenue guidance through the first half of 2028.
Analyst Updates and Market Impact
Leerink Partners adjusted its price target upward from $11 to $12, citing positive developments. Bank of America Securities raised its buy rating target from $8 to $9, though it noted recent sales fell short of expectations. Earlier, after the FDA approval for LAD-1, Leerink increased its target from $9 to $11. Chardan reaffirmed its buy rating with a $11 target.
These updates highlight ongoing momentum in the company’s valuation and stock price trajectory amid key regulatory progress.
